Fraunhofer-Gesellschaft

Publica

Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

A Label-Free Continuous Fluorescence-Based Assay for Monitoring Ornithine Decarboxylase Activity with a Synthetic Putrescine Receptor

 
: Nilam, M.; Gribbon, P.; Reinshagen, J.; Cordts, K.; Schwedhelm, E.; Nau, W.M.; Hennig, A.

:

SLAS discovery 22 (2017), No.7, pp.906-914
ISSN: 2472-5552
ISSN: 2472-5560
European Commission EC
278397; EURHYTHDIA
Chronotherapeutic lifestyle intervention for diabetes and obesity to reset the circadian rhythm and improve cardiometabolic risk in the European working population
Deutsche Forschungsgemeinschaft DFG
HE 5967/4-1, NA 686/11-1
English
Journal Article
Fraunhofer IME ()

Abstract
Polyamines play an important role in cell growth, differentiation, and cancer development, and the biosynthetic pathway of polyamines is established as a drug target for the treatment of parasitic diseases, neoplasia, and cancer chemoprevention. The key enzyme in polyamine biosynthesis is ornithine decarboxylase (ODC). We report herein an analytical method for the continuous fluorescence monitoring of ODC activity based on the supramolecular receptor cucurbit[6] uril (CB6) and the fluorescent dye trans-4-[4-(dimethylamino) styryl]-1-methylpyridinium iodide (DSMI). CB6 has a significantly higher binding constant to the ODC product putrescine (>10(7)M(-1)) than to the substrate L-ornithine (340 M-1). This enables real-time monitoring of the enzymatic reaction through a continuous fluorescence change caused by dye displacement from the macrocycle by the formed product, which allowed a straightforward determination of enzyme kinetic parameters (k(cat) = 0.12 s(-1) and K-M = 24 mu M) and inhibition constants of the two ODC inhibitors alpha-difluoromethylornithine (DFMO) and epigallocatechin gallate (EGCG). The potential for high-throughput screening (HTS) was demonstrated by excellent Z' factors (>0.9) in a microplate reader format, and the sensitivity of the assay is comparable to or better than most established complementary methods, which invariably have the disadvantage of not being compatible with direct implementation and upscaling to HTS format in the drug discovery process.

: http://publica.fraunhofer.de/documents/N-480542.html